Margherita Zipponi

Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neu

Ghanshyam S. Yadav, Dana M. Roque, Stefania Bellone et al. · Gynecologic Oncology · 2022 · 35 citations

Medicine, Oncology, Pharmacology +11

Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma

Justin Harold, Stefania Bellone, Diego Manavella et al. · Gynecologic Oncology · 2022 · 29 citations · Full text

Medicine, Oncology, Pharmacology +13

Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer

Blair McNamara, Cem Demirkiran, Tobias M.P. Hartwich et al. · Gynecologic Oncology · 2024 · 29 citations · Full text

Medicine, Oncology, Pharmacology +16

Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression

Dennis Mauricio, Stefania Bellone, Levent Mutlu et al. · Gynecologic Oncology · 2023 · 26 citations · Full text

Medicine, Oncology, Pharmacology +17

Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor

Joan Tymon‐Rosario, Paola Manara, Diego Manavella et al. · Gynecologic Oncology · 2022 · 25 citations

Medicine, Cancer Biology, Oncology +15